The FY2025 (Dec) proxy of Cerus names 20 peer companies for pay. Pay versus performance data of Cerus for that year is not on file, so it has no rank.
Pay peer group, FY2025 (Dec) proxy
| Akebia Therapeutics [Nasdaq: AKBA] | Not disclosed | Not disclosed |
| AngioDynamics, Inc. [Nasdaq: ANGO] | Not disclosed | Not disclosed |
| Anika Therapeutics [Nasdaq: ANIK] | Not disclosed | Not disclosed |
| Ardelyx, Inc. [Nasdaq: ARDX] | Not disclosed | Not disclosed |
| BioLife Solutions, Inc. [Nasdaq: BLFS] | Not disclosed | Not disclosed |
| CareDX, Inc. [Nasdaq: CDNA] | Not disclosed | Not disclosed |
| Codexis, Inc. [Nasdaq: CDXS] | Not disclosed | Not disclosed |
| Collegium Pharmaceutical, Inc. [Nasdaq: COLL] | Not disclosed | Not disclosed |
| Dynavax Technologies Corp [Nasdaq: DVAX] | Not disclosed | Not disclosed |
| Heron Therapeutics, Inc. [Nasdaq: HRTX] | Not disclosed | Not disclosed |
| Innoviva, Inc. [Nasdaq: INVA] | Not disclosed | Not disclosed |
| Karyopharm Therapeutics Inc. [Nasdaq: KPTI] | Not disclosed | Not disclosed |
| MacroGenics, Inc. [Nasdaq: MGNX] | Not disclosed | Not disclosed |
| MannKind Corporation [Nasdaq: MNKD] | Not disclosed | Not disclosed |
| Mirum Pharmaceuticals, Inc. [Nasdaq: MIRM] | Not disclosed | Not disclosed |
| OmniAb, Inc. [Nasdaq: OABI] | Not disclosed | Not disclosed |
| OraSure Technologies, Inc. [Nasdaq: OSUR] | Not disclosed | Not disclosed |
| Rigel Pharmaceuticals, Inc. [Nasdaq: RIGL] | Not disclosed | Not disclosed |
| Travere Therapeutics, Inc. [Nasdaq: TVTX] | Not disclosed | Not disclosed |
| Vanda Pharmaceuticals, Inc. [Nasdaq: VNDA] | Not disclosed | Not disclosed |
20 companies
Changes by year
FY2025 (Dec) proxy
- RemovedAdma Biologicspay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2025 peer group ADMA Biologics, Inc. and Coherus BioSciences, Inc, primarily based on their market capitalization falling outside the criteria described above
- RemovedCoherus BioSciences, Incpay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2025 peer group ADMA Biologics, Inc. and Coherus BioSciences, Inc, primarily based on their market capitalization falling outside the criteria described above
- RemovedInvitae Corporationpay peer groupIn addition, Invitae Corporation, which was included in our 2024 peer group, was acquired by Labcorp in August 2024 and was, accordingly, removed from our 2025 peer group
FY2024 (Dec) proxy
- RemovedDynavax Technologies Corporationpay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2023 peer group Dynavax Technologies Corporation, Heron Therapeutics, Inc., ImmunoGen, Inc., NanoString Technologies, Inc., Sangamo Therapeutics, Inc., and Veracyte, Inc., primarily based on their market capitalization falling outside the criteria described above
- RemovedHeron Therapeutics, Inc.pay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2023 peer group Dynavax Technologies Corporation, Heron Therapeutics, Inc., ImmunoGen, Inc., NanoString Technologies, Inc., Sangamo Therapeutics, Inc., and Veracyte, Inc., primarily based on their market capitalization falling outside the criteria described above
- RemovedImmunoGen, Inc.pay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2023 peer group Dynavax Technologies Corporation, Heron Therapeutics, Inc., ImmunoGen, Inc., NanoString Technologies, Inc., Sangamo Therapeutics, Inc., and Veracyte, Inc., primarily based on their market capitalization falling outside the criteria described above
- RemovedNanoString Technologies, Inc.pay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2023 peer group Dynavax Technologies Corporation, Heron Therapeutics, Inc., ImmunoGen, Inc., NanoString Technologies, Inc., Sangamo Therapeutics, Inc., and Veracyte, Inc., primarily based on their market capitalization falling outside the criteria described above
- RemovedSangamo Therapeutics, Inc.pay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2023 peer group Dynavax Technologies Corporation, Heron Therapeutics, Inc., ImmunoGen, Inc., NanoString Technologies, Inc., Sangamo Therapeutics, Inc., and Veracyte, Inc., primarily based on their market capitalization falling outside the criteria described above
- RemovedVeracytepay peer groupIn applying these revised peer group selection criteria, our Compensation Committee approved removing from our 2023 peer group Dynavax Technologies Corporation, Heron Therapeutics, Inc., ImmunoGen, Inc., NanoString Technologies, Inc., Sangamo Therapeutics, Inc., and Veracyte, Inc., primarily based on their market capitalization falling outside the criteria described above
FY2023 (Dec) proxy
- RemovedAntares Pharmaceuticals, Inc.pay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
- RemovedCytokineticspay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
- RemovedGlobal Blood Therapeutics Inc.pay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
- RemovedIntersect ENT, Inc.pay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
- RemovedOmerospay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
- RemovedRigel Pharmaceuticalspay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
- RemovedZogenix, Inc.pay peer groupIn applying these revised peer group selection criteria, the Compensation Committee approved removing from our 2022 peer group Omeros Corp., Rigel Pharmaceuticals Inc. and Cytokinetics, Inc. as their market capitalizations fell below (or above, in the case of Cytokinetics, Inc.) the 2023 criteria range and approved removing Antares Pharmaceuticals, Inc., Global Blood Therapeutics Inc., Intersect ENT, Inc. and Zogenix, Inc., as these companies were acquired within the past 12 months
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.